Pages that link to "Q34405016"

The following pages link to Familial amyloid polyneuropathy: new developments in genetics and treatment (Q34405016):

Displaying 20 items.

• A Substructure Combination Strategy To Create Potent and Selective Transthyretin Kinetic Stabilizers That Prevent Amyloidogenesis and Cytotoxicity (Q27658823) (← links)
• Chemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasma (Q27659009) (← links)
• Aromatic Sulfonyl Fluorides Covalently Kinetically Stabilize Transthyretin to Prevent Amyloidogenesis while Affording a Fluorescent Conjugate (Q27675997) (← links)
• Bifunctional coumarin derivatives that inhibit transthyretin amyloidogenesis and serve as fluorescent transthyretin folding sensors (Q27679824) (← links)
• Inhibiting transthyretin conformational changes that lead to amyloid fibril formation (Q27765742) (← links)
• Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity (Q34443897) (← links)
• A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin (Q34576022) (← links)
• Modulating inhibitors of transthyretin fibrillogenesis via sulfation: polychlorinated biphenyl sulfates as models (Q35082885) (← links)
• Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities (Q35813797) (← links)
• Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma (Q35885902) (← links)
• Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy). (Q35995472) (← links)
• Designing conditions for in vitro formation of amyloid protofilaments and fibrils (Q36445068) (← links)
• A current pharmacologic agent versus the promise of next generation therapeutics to ameliorate protein misfolding and/or aggregation diseases (Q37004163) (← links)
• Peripheral Blood Cell Gene Expression Diagnostic for Identifying Symptomatic Transthyretin Amyloidosis Patients: Male and Female Specific Signatures. (Q37202287) (← links)
• Quantification of transthyretin kinetic stability in human plasma using subunit exchange. (Q37688196) (← links)
• The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug (Q37975816) (← links)
• Current and future treatment of amyloid diseases (Q38831388) (← links)
• Gastrointestinal Amyloidosis: Approach to Treatment (Q46144079) (← links)
• A molecular mechanism for transthyretin amyloidogenesis (Q64106153) (← links)
• Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis (Q91943664) (← links)